Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

AIMS: Idarucizumab, a humanized monoclonal anti‐dabigatran antibody fragment, is effective in emergency reversal of dabigatran anticoagulation. Pre‐existing and treatment‐emergent anti‐idarucizumab antibodies (antidrug antibodies; ADA) may affect the safety and efficacy of idarucizumab. This analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Norris, Stephen, Ramael, Steven, Ikushima, Ippei, Haazen, Wouter, Harada, Akiko, Moschetti, Viktoria, Imazu, Susumu, Reilly, Paul A., Lang, Benjamin, Stangier, Joachim, Glund, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Drug Safety
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510069/
https://www.ncbi.nlm.nih.gov/pubmed/28230262
http://dx.doi.org/10.1111/bcp.13269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510069/
https://www.ncbi.nlm.nih.gov/pubmed/28230262
http://dx.doi.org/10.1111/bcp.13269

Ejemplares similares